FDA Releases Laboratory-Developed Tests Final Rule – Thought Leaders in Health Law

Epstein Becker & Green
Contact
The landscape of laboratory testing in the United States is changing.

On April 29, 2024, following more than a decade of discourse, the U.S. Food and Drug Administration (FDA, or the “Agency”) released its long-awaited “Medical Devices; Laboratory Developed Tests” final rule (the “Final Rule”) formalizing the Agency’s authority to regulate laboratory-developed tests (LDTs) as medical devices.

Since the FDA issued its proposed rule (the “Proposed Rule”) in the fall of 2023, See more +

The landscape of laboratory testing in the United States is changing.

On April 29, 2024, following more than a decade of discourse, the U.S. Food and Drug Administration (FDA, or the “Agency”) released its long-awaited “Medical Devices; Laboratory Developed Tests” final rule (the “Final Rule”) formalizing the Agency’s authority to regulate laboratory-developed tests (LDTs) as medical devices.

Since the FDA issued its proposed rule (the “Proposed Rule”) in the fall of 2023, Epstein Becker Green and other industry stakeholders have eagerly awaited the Agency’s issuance of the Final Rule and have speculated as to the provisions of the Proposed Rule that the Agency would choose to finalize.

For now, here are important preliminary takeaways from the Final Rule:

• The FDA intends to exercise different levels of enforcement discretion for certain categories of LDTs.

• The Agency finalized a four-year phase-out structure for implementing the Final Rule.

• Opponents of the Final Rule project increased costs to laboratories of between $2.39 billion and $19.45 billion annually.

• Because the FDA issued the Final Rule before May, a rollback would likely not be possible, even if a new administration takes office after the upcoming presidential election.

What does all of this mean for you?

• Stakeholders should be on the lookout for legal challenges to the Final Rule and lobbying efforts to affect its implementation.

For more information on the Final Rule, see "It’s Been a Long Time Coming – FDA’s Final Rule on Regulation of Laboratory Developed Tests (LDTs) as Medical Devices Has Arrived": https://www.healthlawadvisor.com/its-been-a-long-time-coming-fdas-final-rule-on-regulation-of-laboratory-developed-tests-ldts-as-medical-devices-has-arrived

About Thought Leaders in Health Law

The Thought Leaders in Health Law® video series tracks the latest trends in multiple areas of the health care and life sciences industries, featuring attorneys and advisors from Epstein Becker Green and EBG Advisors. Visit https://www.ebglaw.com/videos-podcasts/thought-leaders-in-health-law and subscribe for email notifications. See less -

Embed
Copy

Other MultiMedia by Epstein Becker & Green

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Epstein Becker & Green | Attorney Advertising

Written by:

Epstein Becker & Green
Contact
more
less

PUBLISH YOUR CONTENT ON JD SUPRA NOW

  • Increased visibility
  • Actionable analytics
  • Ongoing guidance

Epstein Becker & Green on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide